Aug. 13, 2019
Current State of the Art:ATBo+, an amino acid transporter, is elevated in some breast, cervical and colon cancer cells and in intestine epithelial cells. In vivo data also support inhibition of ATBo+ function as a treatment of inflammatory bowel disease.
Disadvantages with the Current Art:Few drugs can kill the cancerous cells without adversely affecting the overall health and quality of life of the patient. Targeting therapeutics with immunotherapy has shown limited success. Treatments for IBD have a variety of adverse effects ranging from nausea and headaches to bone mass loss and increased risk of infection.
The inventors have identified a tryptophan derivative that targets ATBo+, a promising lead target for drug development. The elevated expression of ATBo+ on cancer cells confers a targeting effect with this potential therapy. Cell culture and small animal data were non-toxic to normal cells.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
acid
cancerous
therapeutics
cells
derivatives
ibd
immunotherapy
drugs
atbo
anti-cancer
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium